Katy Rezvani, M.D., Ph.D
@lab_rezvani
Followers
5K
Following
2K
Media
18
Statuses
318
Vice President & Head, Institute of Cell Therapy Discovery & Innovation, MD Anderson Cancer Center
Houston, TX
Joined February 2020
Delighted to share our Cancer Cell paper published today, co-authored by Dr. Alexander Biederstädt @ABiederstadt_MD and Dr. Rafet Basar @rftbsr9 reporting the first genome-wide CRISPR screen in primary cord blood NK and CAR NK cells. We identify key genetic checkpoints including.
Results from a study open new avenues for discovering approaches to enhance the antitumor activity of CAR NK cell therapies against multiple cancer types via a comprehensive CRISPR discovery platform optimized for primary human NK cells. Read more:
9
32
149
Thank you Dr Pisters for attending today’s EAB meeting and for your inspiring vision and steadfast support. Deepest thanks also to our extraordinary EAB members: Drs Carl June, Lewis Lanier, Nicholas Huntington @Dr_Nick_Bikes , John DiPersio, Helen Heslop, Keith Sullivan,.
Pleased to join the first Institute for Cell Therapy Discovery & Innovation's External Advisory Board meeting. With their support and expertise, @MDAndersonNews is well-positioned to translate scientific breakthroughs into powerful cell-based treatments more efficiently, at lower
1
7
43
Congrats to @Dr_Nick_Bikes and team on their Cancer Cell paper! CRISPR screens identify UBE2F and ARIH2 as key brakes on IL-15R signaling in NK cells. Targeting them improves NK & CAR-NK anti-tumor activity, uncovering promising targets for immunotherapy. #NKcells #CAR_NK #IL15.
Excited to share our Cancer Cell @CellPressNews article on the discovery of the IL-15 Receptor "Regulome". A technical tour-de-force from the Immunology, computational biology & functional genomics teams @oNKo_innate @MonashBDI.
4
4
62
Many congrats Alex on this very well-deserved #societyfornaturalimmunity travel award! Your 4 years of work developing GW CRISPR screens in primary CAR-NK cells is paying off! Excited to see how your data will shape the future of NK cell therapy. @MDAndersonNews #NK2025.
Back from an amazing #NK2025! 🧬✨ Honored to present our work on genome-wide CRISPR screens to boost CAR-NK cell potency💥Immensely grateful to my incredible mentor, @lab_rezvani 🙏🌟 for her support and to the #SocietyforNaturalImmunity for the travel award🙌 #NKcells #ACT
2
6
61
incredible team of collaborators whose hard work made this possible. Excited to explore the translation of this approach to the clinic. @mdandersonnews #NK #immunotherapy #NK.
0
2
22
Please check out our paper published today in Nature that identifies CREM as a key checkpoint limiting CAR NK cell function.CRISPR knockout of CREM significantly enhanced anti-tumor activity, implicating a broader role in NK cell regulation. Huge congrats to @hindrafei and our.
12
27
204
Hind, many congratulations on this important work & sincere thanks to the brilliant co-authors who made it possible. I’m so proud of all you’ve achieved and wish you every success as you begin your independent career. Excited to see what comes next!
🧵14/.This work wouldn’t have been possible without the incredible mentorship of @lab_rezvani, the brilliance of our lab members, our co-authors, and the generous support of our collaborators Dr. Toszka Bohn, Dr. Tobias Bopp, Sebastian Kunz, Dr. Huihui Fan, @abhinavjain_phd,.
2
3
49
RT @BLLPHD: Treating the untreatable - "Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure".@PennMedicine @nejm.#immunotherapy….
0
60
0
Congratulations to @ABiederstadt_MD on an outstanding presentation #AACR25, showcasing a novel platform for genome-wide CRISPR screening in primary human CAR NK cells. So proud of your achievements and excited to watch your continued impact in the field. #NKcells @MDAndersonNews
3
10
94
Congratulations! Looking forward to your presentation. I have no doubt it’ll be amazing!.
Very excited to share our work on targeting a checkpoint induced by CAR and cytokine signaling and exchange ideas at the Adoptive Cell Therapies session co-chaired by @sidichen @DJPowellLab at #AACR25. I hope to see you there 😊! @lab_rezvani @MDAndersonNews . AACR: MD Anderson.
0
2
28
RT @AACR: The AACR congratulates Crystal L. Mackall, MD, FAACR, who will be honored with the 2025 AACR-@CancerResearch Lloyd J. Old Award i….
0
3
0
Brilliant work! congratulations, @may_daher and @CollaSimona and co-authors. Fascinating insight into how early NK cell dysfunction contributes to immune escape in MDS, and a compelling case for the therapeutic potential of adoptive NK cell transfer. Looking forward to seeing.
Very excited to share our latest research article published with @SpringerNature in @NatureComms. We show that in early #MDS, NK cells share mutations with the malignant clones, becoming dysfunctional and failing to eliminate aberrant stem cells. This leads to immune evasion and.
1
6
58
RT @sanamloghavi: Dear Leukemia friends, making U aware of this exceptional MDS symposium organized by Dr. @CollaSimona at @MDAndersonNews….
0
27
0
Please check out our paper published in @NatureMedicine on our Phase I trial of AFM13-precomplexed cord blood NK cells in relapsed/refractory CD30+ lymphomas. Led by Dr. Yago Nieto and an outstanding team of coauthors and collaborators, this study marks the first clinical.
Findings from a Phase I trial suggest natural killer cells pre-complexed with AFM13 has promise for specific patients with lymphoma and may be adapted for more cancer types in the future. Learn more: #EndCancer.
16
52
168
RT @LabWaggoner: Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells @ImmunityCP….
0
19
0
Thank you Dr. Pisters - it was an honor to share the progress being made at the Institute for Cell Therapy Discovery & Innovation! Very grateful to @GHPartnership for the opportunity to showcase our efforts to bring .transformative cell therapies to patients. Looking forward to.
It was a superb @GHPartnership Board Meeting today as @MDAndersonNews' Dr. Katy Rezvani shared the groundbreaking work underway within the Institute for Cell Therapy Discovery & Innovation. This area of science continues to develop in tremendous ways for the benefit of patients
2
9
53
Congratulations to Dr. Rafet Basar for his outstanding presentation at ASTCT on the promise of cord blood therapies. His talk highlighted our work on engineered NK cells. Grateful for his amazing contributions to the field! #NKCells #ASTCT @MDAndersonNews @rftbsr9
5
7
65